- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Chi shares follow-up data on niraparib/abiraterone combo in BRCA+ mCRPC
“These data from the MAGNITUDE study demonstrate the risk-benefit profile for the combination of niraparib plus abiraterone acetate for patients with metastatic CRPC and BRCA mutations and establishes a new standard of care for these patients,” says Kim Nguyen N. Chi, MD, FRCPC.
In this video, Kim Nguyen N. Chi, MD, FRCPC, a professor in the department of medicine at the University of British Columbia in Vancouver, Canada, highlights updated findings and overall take-home messages from the MAGNITUDE trial (NCT03748641), whichexplored the combination of niraparib plus abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer. Chi presented the findings at the 2023 European Society for Medical Oncology Annual Congress in Madrid, Spain.
Video Transcript:
What were the key findings presented at ESMO?
This analysis was focused on the patients with BRCA-mutated metastatic CRPC. Now, right from the start, we did see that there was a numerical imbalance in some key prognostic features. Particularly, in the patients in the placebo group, they had a more favorable prognosis; here were fewer patients with an ECOG performance status of 1, there were fewer patients with bone metastases, and there were also fewer patients with visceral metastasis. So, in the final overall survival results, there was a benefit of niraparib that was in favor for overall survival. In the multivariate analysis, this incorporated key prognostic factors, including those that were numerically imbalanced in favor of the placebo arm, and we saw a greater overall survival benefit supporting the overall survival benefit of niraparib plus abiraterone.
In the first analysis we did see benefits for niraparib of for the key patient-centric end points of time to cytotoxic chemotherapy and time to symptomatic progression. We continued to see that benefit with the final analysis. There was an early spread of the curves and that continued with longer follow-up, with improvements of over 40%.
What is the overall take-home message from this study?
These data from the MAGNITUDE study demonstrate the risk-benefit profile for the combination of niraparib plus abiraterone acetate for patients with metastatic CRPC and BRCA mutations and establishes a new standard of care for these patients.
This transcription has been edited for clarity.
